KR20230079151A - Kdm1a 에 의해 매개되는 질환 치료용 약학 제형 - Google Patents

Kdm1a 에 의해 매개되는 질환 치료용 약학 제형 Download PDF

Info

Publication number
KR20230079151A
KR20230079151A KR1020237014383A KR20237014383A KR20230079151A KR 20230079151 A KR20230079151 A KR 20230079151A KR 1020237014383 A KR1020237014383 A KR 1020237014383A KR 20237014383 A KR20237014383 A KR 20237014383A KR 20230079151 A KR20230079151 A KR 20230079151A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
composition according
compound
amount
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237014383A
Other languages
English (en)
Korean (ko)
Inventor
에이미 테퍼
카산드라 셀라트카
패트리샤 술리악
파라그 베드
남라타 보라
Original Assignee
이마고 바이오사이언시즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이마고 바이오사이언시즈 인코포레이티드 filed Critical 이마고 바이오사이언시즈 인코포레이티드
Publication of KR20230079151A publication Critical patent/KR20230079151A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020237014383A 2020-10-01 2021-10-01 Kdm1a 에 의해 매개되는 질환 치료용 약학 제형 Pending KR20230079151A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063086353P 2020-10-01 2020-10-01
US63/086,353 2020-10-01
PCT/US2021/053141 WO2022072811A1 (en) 2020-10-01 2021-10-01 Pharmaceutical formulations for treating diseases mediated by kdm1a

Publications (1)

Publication Number Publication Date
KR20230079151A true KR20230079151A (ko) 2023-06-05

Family

ID=80951023

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237014383A Pending KR20230079151A (ko) 2020-10-01 2021-10-01 Kdm1a 에 의해 매개되는 질환 치료용 약학 제형

Country Status (10)

Country Link
US (1) US20230293495A1 (https=)
EP (1) EP4221704B1 (https=)
JP (1) JP7848195B2 (https=)
KR (1) KR20230079151A (https=)
CN (1) CN116367831A (https=)
AU (1) AU2021351536A1 (https=)
BR (1) BR112023005987A2 (https=)
CA (1) CA3193661A1 (https=)
MX (1) MX2023003783A (https=)
WO (1) WO2022072811A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250295660A1 (en) 2022-05-09 2025-09-25 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
EP4522136A1 (en) 2022-05-09 2025-03-19 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
TW201431552A (zh) 2008-07-28 2014-08-16 Takeda Pharmaceutical 醫藥組成物
US20100273825A1 (en) * 2009-03-30 2010-10-28 Astellas Pharma Inc. Solid pharmaceutical composition containing solifenacin amorphous form
RU2627471C2 (ru) * 2011-09-14 2017-08-08 Селджин Корпорейшн Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты
WO2015170237A1 (en) * 2014-05-05 2015-11-12 Torrent Pharmaceuticals Limited Stable solifenacin composition
CA2976350C (en) * 2015-02-12 2023-09-19 Hugh Young Rienhoff, Jr. Kdm1a inhibitors for the treatment of disease
US20190070172A1 (en) * 2015-11-05 2019-03-07 Imago Biosciences, Inc. Lysine-specific histone demethylase as a novel therapeutic target in myeloproliferative neoplasms
TWI833686B (zh) 2016-04-22 2024-03-01 美商英塞特公司 Lsd1 抑制劑之調配物
CN111194306B (zh) * 2016-08-16 2023-05-16 伊美格生物科学公司 用于制备kdm1a抑制剂的方法和过程
KR20220113753A (ko) * 2019-12-09 2022-08-16 이마고 바이오사이언시즈 인코포레이티드 골수증식성 신생물의 치료를 위한 리신-특이적 히스톤 데메틸라제 억제제

Also Published As

Publication number Publication date
CN116367831A (zh) 2023-06-30
WO2022072811A1 (en) 2022-04-07
EP4221704A1 (en) 2023-08-09
MX2023003783A (es) 2023-04-26
EP4221704A4 (en) 2024-11-06
BR112023005987A2 (pt) 2023-05-02
EP4221704B1 (en) 2025-09-24
JP2023544327A (ja) 2023-10-23
US20230293495A1 (en) 2023-09-21
JP7848195B2 (ja) 2026-04-20
CA3193661A1 (en) 2022-04-07
AU2021351536A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
RU2405540C1 (ru) Таблетка с высоким содержанием лекарственного препарата
US20230293495A1 (en) Pharmaceutical formulations for treating diseases mediated by kdm1a
EP3409272B1 (en) Pharmaceutical composition comprising eltrombopag olamine, reducing sugar, and polymeric binder
CN102137663B (zh) 抑制变色的稳定的药物制剂
AU2018326596A1 (en) High concentration dosage forms of pridopidine
WO2019149917A1 (en) A pharmaceutical composition comprising metamizole, drotaverine, and caffeine
US9572806B2 (en) Elution-stabilized preparation
EP3437645B1 (en) Film-coated tablet having high chemical stability of active ingredient
CN103717209B (zh) 速释的含普拉格雷的稳定的口服药物组合物
KR20160060764A (ko) 아타자나비르 및 코비시스타트의 ｈｉｖ 치료 제제
EP2538924B1 (en) Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation
BR112020019425A2 (pt) Composição farmacêutica compreendendo meta-arsenito e método de fabricação
AU2014326142B2 (en) Pharmaceutical composition comprising capecitabine and cyclophosphamide
KR20180036633A (ko) 용출율이 향상된 라록시펜, 및 비타민 d 또는 그 유도체를 포함하는 복합 캡슐제 및 이의 제조방법
KR20150059720A (ko) 아나글립틴 함유 제제
KR20160092956A (ko) 라록시펜, 및 비타민 d 또는 그 유도체를 포함하는 복합 캡슐제
CN101485637B (zh) 秋水仙碱骨架控释片或胶囊
CN105311635A (zh) 可调控释放度的高载药量的医药组合物及其制备方法
EA051661B1 (ru) Фармацевтическая композиция для лечения заболеваний, опосредованных kdm1a
EP4736851A1 (en) Levodopa-benserazide hydrochloride composition and preparation therefor
JP2025524357A (ja) 多数の顆粒
JP2025036080A (ja) グアンファシンを含む医薬組成物及びその製造方法
WO2025206292A1 (ja) アコチアミド又はその塩高含有錠剤
JP2022536955A (ja) ジクロフェナミド組成物及び使用方法
KR102065090B1 (ko) 레베티라세탐 또는 이의 약제학적으로 허용되는 염을 함유하는 서방성 제제 및 이의 제조방법

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230427

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240930

Comment text: Request for Examination of Application

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241002

Comment text: Request for Examination of Application